Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, ...

The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...

The experimental mRNA shot, tested in macaques, generated a stronger immune response and dramatically reduced the number of ...

Moderna’s stock has seen an extended downtrend since peaking above $480 in late 2021. After crashing to below $70 in November last year, the stock experienced a strong medium-term rally that took it ...

Moderna shares are moving higher on Tuesday after the company announced that Health Canada approved its updated COVID-19 ...

Moderna has vowed to cut annual R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more ...

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

It has been more than 60 years since the virus causing mpox was discovered. The mRNA COVID-19 vaccines were first ...

As part of a broad restructuring, the company revealed plans to reduce research spending by 20% over the next few years and ax five programs in early development. It won’t cut jobs, however, a ...

COVID-19 numbers are on the rise across the state of Indiana, and few Hoosiers are up to date on their vaccinations for the ...

Moderna, once a shining star in the pharmaceutical industry for its rapid development of COVID-19 vaccines, is now facing a ...

Also on Thursday, Moderna announced positive late-stage trial results on its vaccine against respiratory syncytial virus in high-risk adults ages 18 to 59, with plans to file for approval for that age ...